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Colorectal cancer (CRC), or bowel cancer, is a
significant health problem in many western countries,
including Australia. While the underlying causes are still
unclear, there is now good evidence that screening is
effective in reducing deaths from CRC, by facilitating the
detection and removal of curable cancers.1-3 However,
there are many issues still to be resolved before screening
can be implemented in the most effective and appropriate
way in the Australian setting.
There is no simple answer to the question ‘How
should colorectal cancer screening be implemented?’
This is because there are different ways of reaching the
target population and different types of screening tests,
each with their own particular advantages or
disadvantages. Within the target population, there are
sub-groups with different levels of risk who ideally require
different approaches to screening. The uncertainties and
complexities of how to implement CRC screening in
Australia can be illustrated by briefly describing some
initiatives and studies being undertaken by a group
affiliated with Flinders University, Adelaide University and
CSIRO. Over the last 5 years this group, based at Flinders
Medical Centre (FMC) and the Repatriation General
Hospital (RGH), Daw Park, and operating as the Bowel
Health Service, has been undertaking research into
screening for CRC. More recently, the group has been
expanded to include behavioural scientists from Adelaide
University and CSIRO.
Options for CRC screening.
There is evidence to support the use of colonoscopy,
flexible sigmoidoscopy and faecal occult blood testing
(FOBT) as possible population screening modalities. Other
methods of detecting colonic lesions include radiological
methods (barium enema or virtual colonoscopy /CT
colonography), digital rectal examination, and DNA based
faecal tests. These methods are either unsuitable as
screening modalities or have not yet been proven as
effective in a population screening setting.
Colonoscopy is regarded as the most sensitive test,
but cost, access, the procedure itself and possible
complications limit its wider use in a screening setting.
However, colonoscopy allows immediate polyp removal
and, if no lesions are found in a person at average risk,
the procedure need not be repeated for 5 years.
Flexible sigmoidoscopy allows the lower bowel to
be examined and is less complicated than colonoscopy.
Flexible sigmoidoscopy can be combined with FOBT to
improve test sensitivity.
FOBTs are effective because they detect blood that
may be derived from cancers and adenomas. Positive
tests identify people who have an increased risk of CRC
and who require follow-up colonoscopy to determine the
source of occult blood. FOBTs are simple, inexpensive
and non-invasive; samples for testing can be collected at
home. But the tests are less sensitive than colonoscopy
and require repeating every 1-2 years.
Chemical (guaiac)-based FOBTs were used in studies
that demonstrated the benefit of screening for reducing
CRC mortality. There are now newer immunochemical
FOBTs (faecal immunochemical tests or FITs) that have
potential advantages, and many of our studies are based
on the use of these new-generation FOBTs. Some of the
key activities of the Bowel Health Service are briefly
described below and help to illustrate some of the
uncertainties that still relate to CRC screening.
Evaluation of new FOBTs
The studies giving evidence that FOBT-based
screening is effective in reducing mortality from CRC
used guaiac-based tests, in which the chemical activity
of haem indicates the presence of haemoglobin in faecal
samples. These guaiac tests require dietary and medication
restrictions to increase specificity and are not specific
for colonic haemoglobin. Newer FITs detect the globin
portion of human haemoglobin; they do not cross-react
with dietary components or medications, and are specific
for colonic blood. We directly compared the performance
of guaiac and immunochemical tests for their ability to
detect cancers (and adenomas). While these studies are
ongoing, preliminary data indicates that immunochemical
tests have the higher sensitivity to cancer and large
adenomas while maintaining test specificity.
Screening for colorectal cancer:
Update on some current research in Adelaide
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Screening the above-average risk group
Surveillance is recommended for people with a
significant family or personal history of CRC or colonic
adenomas (polyps). For FMC and RGH patients, this
meant that people were periodically recalled for
surveillance colonoscopy, though an audit revealed that
many patients were not receiving surveillance according
to NHMRC guidelines.5 The Southern Cooperative Program
for the Prevention of Colorectal Cancer (SCOOP) was
created to provide improved CRC surveillance services
for this above-average risk group on the FMC and RGH
colonoscopy recall databases. Strategies included GP
education, CRC risk assessment, colonoscopy recall and
FOBT screening components.
GP education programs have resulted in greater
awareness about and more appropriate referrals to the
surveillance program. Reassessment of CRC risk levels
has allowed more rational (usually increased) intervals to
be determined, and audits have shown that the new
intervals are now being closely adhered to, thus freeing
up valuable colonoscopy resources.
The NHMRC has recently recommended that FOBT-
based screening should be considered as an additional
surveillance test, in years when colonoscopy is not
performed.5 We have introduced FOBT screening in this
group and are now well into a 5-year evaluation program.
Results so far indicate that these patients are willing to
participate in screening, and some have been diagnosed
with cancers or adenomas through the screening program.
It is not known whether these lesions developed rapidly,
or whether they were missed at a previous colonoscopy,
but the fact that FOBT-screening does reveal further
neoplasia, and earlier than if only colonoscopy was used,
is clearly of benefit.
Screening the average risk group - population
screening.
One of the biggest challenges to FOBT-based
population screening is simply to get people to complete
the screening test. Without participation there is no
detection, and participation rates in large screening trials
have been typically 30-40%, well below the 70% target
proposed and the goal for other cancer screening
programs. A number of studies are underway that aim
to determine the effect of various program variables on
screening participation rates.
The effect of diet on participation
Client groups were offered a guaiac-based FOBT
(Hemoccult, Beckman-Coulter) which required a modified
diet during sample collection, or an immunochemical test
(FlexSure, Beckman Coulter) which required no dietary
modification. Participation was significantly lower in the
group offered Hemoccult, indicating that dietary restriction
has a strong negative effect on participation.6
The effect of improved test technology
One FIT that has recently been developed (InSure,
Enterix) incorporates an improved brush (rather than
spatula) sampling process, coupled with a decrease in
the number of faecal samples required, from three to
two. We reasoned that these technological differences
were likely to attract more participants. Three groups of
invitees were offered screening using FOBTs that differed
in their level of technology. We found that the highest
level of participation was obtained in the group offered
an FOBT incorporating technological improvements.7
The effect of the GP on participation
When considering how to implement screening
programs, options include a centralised screening service
and programs based around general practices. The GP
has a powerful influence on health behaviours, and we
reasoned that screening offers endorsed by a GP might
improve CRC screening rates. People could be screened
either by invitation from the Bowel Health Service, or
through their general practice with two levels of GP
endorsement. Invitations signed by a GP resulted in a
significantly higher level of screening participation (43.5%)
compared to invitations that only indicated practice support
(40.1%), or those received directly from the central Bowel
Health Service (34.0%).8
Differences between participants and non-participants
Our research trials allowed us to identify groups
of participants and non-participants. We reasoned that
the identification of differences between these groups
could provide insights into key factors associated with
screening behaviour. We developed a specific
questionnaire to survey demographic, behavioural and
psychosocial characteristics, and surveyed the two groups.
We found that non-participants were more likely to find
faecal sampling distasteful, while participants saw more
value in screening and were more likely to attend future
screening. This information can potentially be used to
inform new strategies to overcome barriers to screening
participation.
Development of a flexible sigmoidoscopy service
Flexible sigmoidoscopy is an effective screening
modality for people at average risk of CRC, especially
when performed together with FOBT. To increase
screening options without impacting on colonoscopy
services, the first nurse endoscopist in Australia has been
trained and, in a nurse practitioner role, now undertakes
flexible sigmoidoscopy screening  at the Repatriation
General Hospital.
Taken together, these research studies and initiatives
demonstrate the commitment of this group of researchers
and clinicians to the prevention of colorectal cancer
through screening and early detection.
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Other CRC screening initiatives in Adelaide.
Although not directly linked to our studies, a feasibility
trial of population screening, the Federal Bowel Cancer
Screening Pilot, is currently being conducted in selected
postcodes in Adelaide, Melbourne and Mackay. While
this trial is incomplete, early results indicate that it has
been well received. It is hoped that this feasibility trial
will ultimately lead to the introduction of an Australia-
wide population-screening program for prevention of
CRC.
Any questions relating to these research studies can
be directed to the Bowel Health Service, Repatriation
General Hospital on 08 8275 1075. Information about the
SCOOP program can be obtained by calling 08 8204
8902.
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Recommendations from optimising cancer care in
Australia
The treatment experience and the quality and length of life
of most people with cancer can be greatly improved if these
recommendations are implemented. The three main themes
predominating in these recommendations are quality, access
and resourcing.
1. Integrated multi-disciplinary care:
• that investigation of the incentives required to foster,
maintain and evaluate integrated multi-disciplinary care
in both the public and private sectors be undertaken.
2. Improving the cancer journey:
• that a national process of quality-driven organisational
reform be implemented to improve ongoing consumer
access to information, palliative and supportive care
 throughout the cancer journey.
3. Voluntary accreditation:
• that a system of voluntary accreditation for Australian
cancer care services be developed, broadly modelled
on that of the U.S. Commission on Cancer.
4. Access to clinical trials:
• that the capacity to undertake clinical trials be increased,
including development of a public register of trials.
5. Workforce:
• that the recommendations of the National Strategic 
Plan for Radiation Oncology and the Specialist 
Haematological and Medical Oncology Workforce in 
Australia be implemented urgently and
6. • that the Australian Health Workforce Advisory 
Committee consider the entire non-medical cancer 
care workforce, especially cancer nurses, radiation 
physicists and radiation therapists as a priority.
7. Psycho-oncology:
• that the need for psychologists and/or other 
appropriately trained health professionals be brought 
to the attention of the Australian Health Ministers 
Advisory Council.
8. Radiation oncology:
• that the recommendations of the National Strategic 
Plan for Radiation Oncology be implemented.
9. Access to pharmaceuticals:
• that a ministerial working party review and develop 
solutions to the problems of access  to new and old 
cancer drugs.
10.  Access to support for travel:
• that there be a review of matters affecting access to 
cancer care, including travel to  and from treatment 
centres.
11. Equity of access:
• that the needs of special populations be the focus of
efforts to narrow gaps in access to and utilisation of 
culturally sensitive services.
12.  A national taskforce on cancer:
• that a national taskforce be established to drive the 
reform process.
There are, in addition, 19 other action items which can be
accessed at: www.ncci.org.au.
